Cancer immunoprevention

Current Opinion in Immunology

Volumn 39, Issue , 2016, Pages 52-58

  Finn, Olivera J ^a   Beatty, Pamela L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOLOGICAL ADJUVANT; MESOTHELIN; MUCIN 1; PROTEIN E6; PROTEIN E7; SIPULEUCEL T; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C RECEPTOR; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIGEN EXPRESSION; BREAST CANCER; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOPREVENTION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL STUDY; COLON CANCER; DRUG TARGETING; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; HIGH RISK POPULATION; HISTORY OF MEDICINE; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOREGULATION; IMMUNOSURVEILLANCE; LUNG CANCER; MEDICAL PRACTICE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; PANCREAS CANCER; PATIENT IDENTIFICATION; PROSTATE CANCER; REVIEW; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; UTERINE CERVIX DYSPLASIA; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY; NEOPLASMS; PHYSIOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; CANCER VACCINES; HUMANS; IMMUNITY, INNATE; NEOPLASMS;

EID: 84954461709     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.01.002     Document Type: Review

References (53)

1. Adams S., Gray R.J., Demaria S., Goldstein L., Perez E.A., Shulman L.N., Martino S., Wang M., Jones V.E., Saphner T.J., et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014, 32:2959-2966.
2. Azimi F., Scolyer R.A., Rumcheva P., Moncrieff M., Murali R., McCarthy S.W., Saw R.P., Thompson J.F. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012, 30:2678-2683.
3. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
4. Loi S., Michiels S., Salgado R., Sirtaine N., Jose V., Fumagalli D., Kellokumpu-Lehtinen P.L., Bono P., Kataja V., Desmedt C., et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014, 25:1544-1550.
5. Sharma P., Allison J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015, 161:205-214.
6. Lipson E.J., Forde P.M., Hammers H.J., Emens L.A., Taube J.M., Topalian S.L. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 2015, 42:587-600.
7. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
8. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
9. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
10. Ferris R.L., Lu B., Kane L.P. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol 2014, 193:1525-1530.
11. Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Kuchroo V., Zarour H.M. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010, 207:2175-2186.
12. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
13. Whiteside T.L. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010, 10:1019-1035.
14. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
15. Trepo C. A brief history of hepatitis milestones. Liver Int 2014, 34(Suppl. 1):29-37.
16. Wei X.X., Fong L., Small E.J. Prostate cancer immunotherapy with sipuleucel-T: current standards and future directions. Expert Rev Vaccines 2015, 14:1529-1541.
17. Farkas A.M., Finn O.J. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin Immunol 2010, 22:125-131.
18. Husemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., Forni G., Eils R., Fehm T., Riethmuller G., et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
19. Singh K., Lester J., Karlan B., Bresee C., Geva T., Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol 2013, 208:e321-e326.
20. de Paula Peres L., da Luz F.A., Dos Anjos Pultz B., Brigido P.C., de Araujo R.A., Goulart L.R., Silva M.J. Peptide vaccines in breast cancer: the immunological basis for clinical response. Biotechnol Adv 2015.
21. Finn O.J. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res 2014, 2:708-713.
22. Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., Mellman I., Prindiville S.A., Viner J.L., Weiner L.M., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15:5323-5337.
23. Adams S., Greeder L., Reich E., Shao Y., Fosina D., Hanson N., Tassello J., Singh B., Spagnoli G.C., Demaria S., et al. Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?. Cancer Immunol Immunother 2011, 60:999-1007.
24. Chen Y.T., Panarelli N.C., Piotti K.C., Yantiss R.K. Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions. Cancer Immunol Res 2014, 2:480-486.
25. Piotti K.C., Scognamiglio T., Chiu R., Chen Y.T. Expression of cancer/testis (CT) antigens in squamous cell carcinoma of the head and neck: evaluation as markers of squamous dysplasia. Pathol Res Pract 2013, 209:721-726.
26. Winter J.M., Tang L.H., Klimstra D.S., Brennan M.F., Brody J.R., Rocha F.G., Jia X., Qin L.X., D'Angelica M.I., DeMatteo R.P., et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS ONE 2012, 7:e40157.
27. Frank R., Li S., Ahmad N.A., Sepulveda A.R., Jhala N.C. Mesothelin expression in pancreatic mucinous cysts. Am J Clin Pathol 2014, 142:313-319.
28. Yonezawa S., Higashi M., Yamada N., Goto M. Precursor lesions of pancreatic cancer. Gut Liver 2008, 2:137-154.
29. de Roos M.A., van der Vegt B., Peterse J.L., Patriarca C., de Vries J., de Bock G.H., Wesseling J. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast. Histopathology 2007, 51:227-238.
30. Broussard E.K., Kim R., Wiley J.C., Marquez J.P., Annis J.E., Pritchard D., Disis M.L. Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions. Cancer Prev Res (Phila) 2013, 6:666-674.
31. Ebben J.D., Lubet R.A., Gad E., Disis M.L., You M. Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: an in vivo study in a murine model of EGFR mutant lung cancer. Mol Carcinog 2015.
32. Nasti T.H., Rudemiller K.J., Cochran J.B., Kim H.K., Tsuruta Y., Fineberg N.S., Athar M., Elmets C.A., Timares L. Immunoprevention of chemical carcinogenesis through early recognition of oncogene mutations. J Immunol 2015, 194:2683-2695.
33. Abrams S.I., Hand P.H., Tsang K.Y., Schlom J. Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 1996, 23:118-134.
34. Carbone D.P., Ciernik I.F., Kelley M.J., Smith M.C., Nadaf S., Kavanaugh D., Maher V.E., Stipanov M., Contois D., Johnson B.E., et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 2005, 23:5099-5107.
35. Vermeij R., Leffers N., Melief C.J., Daemen T., Nijman H.W. Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. Curr Pharm Des 2012, 18:3804-3811.
36. Kao H., Marto J.A., Hoffmann T.K., Shabanowitz J., Finkelstein S.D., Whiteside T.L., Hunt D.F., Finn O.J. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001, 194:1313-1323.
37. Dai L., Li J., Ortega R., Qian W., Casiano C.A., Zhang J.Y. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens. J Immunol Res 2014, 2014:827827.
38. Dhodapkar M.V., Krasovsky J., Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci U S A 2002, 99:13009-13013.
39. Dhodapkar M.V., Krasovsky J., Osman K., Geller M.D. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003, 198:1753-1757.
40. Dhodapkar M.V., Sexton R., Waheed S., Usmani S., Papanikolaou X., Nair B., Petty N., Shaughnessy J.D., Hoering A., Crowley J., et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014, 123:78-85.
41. Blotta S., Tassone P., Prabhala R.H., Tagliaferri P., Cervi D., Amin S., Jakubikova J., Tai Y.T., Podar K., Mitsiades C.S., et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood 2009, 114:3276-3284.
42. Spisek R., Kukreja A., Chen L.C., Matthews P., Mazumder A., Vesole D., Jagannath S., Zebroski H.A., Simpson A.J., Ritter G., et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007, 204:831-840.
43. Dhodapkar M.V., Sexton R., Das R., Dhodapkar K.M., Zhang L., Sundaram R., Soni S., Crowley J.J., Orlowski R.Z., Barlogie B. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 2015, 126:2475-2478.
44. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
45. de Vos van Steenwijk P.J., Ramwadhdoebe T.H., Lowik M.J., van der Minne C.E., Berends-van der Meer D.M., Fathers L.M., Valentijn A.R., Oostendorp J., Fleuren G.J., Hellebrekers B.W., et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother 2012, 61:1485-1492.
46. de Vos van Steenwijk P.J., van Poelgeest M.I., Ramwadhdoebe T.H., Lowik M.J., Berends-van der Meer D.M., van der Minne C.E., Loof N.M., Stynenbosch L.F., Fathers L.M., Valentijn A.R., et al. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol Immunother 2014, 63:147-160.
47. Kimura T., McKolanis J.R., Dzubinski L.A., Islam K., Potter D.M., Salazar A.M., Schoen R.E., Finn O.J. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 2013, 6:18-26.
48. Ajioka Y., Watanabe H., Jass J.R. MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. J Clin Pathol 1997, 50:417-421.
49. Ho S.B., Ewing S.L., Montgomery C.K., Kim Y.S. Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence. Oncol Res 1996, 8:53-61.
50. Kimura T., Finn O.J. MUC1 immunotherapy is here to stay. Expert Opin Biol Ther 2013, 13:35-49.
51. Beatty P.L., Narayanan S., Gariepy J., Ranganathan S., Finn O.J. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila) 2010, 3:438-446.
52. Beatty P., Ranganathan S., Finn O.J. Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology 2012, 1:263-270.
53. Banday A.H., Jeelani S., Hruby V.J. Cancer vaccine adjuvants-recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol 2015, 37:1-11.